About this trial
The purpose of this trial is to determine the link between the development of toxicity following treatment and a genetic variation.
The first aim is to determine the relationship of skin and/or eye toxicity following treatment with Cetuximab or Panitumumab and a genetic variation known as a single nucleotide polymorphism.
The second aim is to investigate the relationship between disease response and the profile of the genetic variation (single nucleotide polymorphism).
Eligible patients for this study would have;
- Stage 4 colorectal cancer expressing a mutated gene known as KRAS.
- Stage 4 non-small cell lung cancer expressing a protein known as epidermal growth factor receptor (EGFR).
- No previous treatment with Cetuximab or Panitumumab .
- Planned treatment of either Cetuximab or Panitumumab.
Where’s this trial being run?Beaumont Hospital, Bon Secours Cork, Cork University Hospital, Sligo University Hospital, Tallaght University Hospital, University Hospital Galway, University Hospital Waterford, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Correlation of Single Nucleotide Polymorphism (SNP) profile of domain III of EGFR to skin and/or eye toxicity and disease response to treatment with Cetuximab or Panitumumab
|Principal Investigator:||Dr Michael Martin (Sligo University Hospital)|
This is an investigator-led study sponsored by Cancer Trials Ireland
Global: Not Applicable
Ireland: June 2011
|Global Recruitment Target:||Not Applicable|
|Ireland Recruitment Target:||150|